Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials. - Francoeur AA; Liang SY; File B; Choi E; Brameld M; Richardson MT; Johnson CR; Kapp DS; Tewari KS; Chan JK (Gynecologic oncology reports, 2026)